Loading stock data…
TCRT
$2.61+0.06 (+2.35%)
Market ClosedLast close May 1
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alaunos Therapeutics, Inc. in the Healthcare sector is trading at $2.61. The stock is currently 58% below its 52-week high of $6.20, remaining 10.6% below its 200-day moving average. Technical signals show oversold RSI of 27 and bearish MACD signal, explaining why TCRT maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 27) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.61
Potential Upside
5%
Whystock Fair Value$2.74
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.49M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.13
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-193.96%
Volume
Today's trading volume
11,491
Recent News
Ziopharm: Q3 Earnings Snapshot
HOUSTON (AP) — Alaunos Therapeutics, Inc. TCRT) on Friday reported a loss of $1.2 million in its third quarter. The Houston-based company said it had a loss of 55 cents per share.
Ziopharm: Q2 Earnings Snapshot
HOUSTON (AP) — Alaunos Therapeutics, Inc. TCRT) on Thursday reported a loss of $1.1 million in its second quarter. On a per-share basis, the Houston-based company said it had a loss of 63 cents.